Macrolide Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Macrolide Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

1
1

Macrolides is a class of antibacterial drugs that contain a large macrocyclic lactone ring substituted with certain unusual sugars. This class comprises drugs that inhibit protein synthesis in harmful and infectious gram-positive bacteria. These molecules bind to the 50S ribosomal unit, thereby restricting the ribosomes from carrying out the bacterial protein synthesis. Protein synthesis in bacteria is inhibited by macrolide drugs. Macrolide drugs are primarily bacteriostatic; however, they may be bactericidal at high concentrations or depending on the type of bacterial strain. These drugs were first extracted from Streptomyces erythraeus. The drug was named erythromycin back in the 1950s. Two other synthetic derivatives viz. clarithromycin and azithromycin were later developed by utilizing erythromycin in the 1970s and 1980s respectively.

Macrolides have a broad spectrum of activity and are effective against several bacterial strains of StreptococcusClostridiumCorynebacteriumHaemophilusListeriaLegionellaStaphylococcusMycoplasma sp., and Neisseria meningitidis. Macrolide drugs are active against gram-positive bacteria, as they can easily penetrate the cell walls of gram-positive bacteria. Neither peptidoglycan (present in bacterial cell walls) nor the cytoplasmic membrane act as a barrier to these molecules when they enter the cell walls of gram-positive bacteria. However, macrolides are inactive in case of a gram-negative bacteria, as they are unable to penetrate the cell walls of gram-negative bacteria. This is because the outer membrane of these cells is hydrophilic with aqueous porins and on the other hand, macrolides are lyophilic in nature.

Some of the major antibacterial drugs that belong to the macrolide drug class are erythromycin, clarithromycin, azithromycin, dirithromycin, roxithromycin, troleandomycin, fidaxomicin, and telithromycin. Macrolides accounted for 7.0% share of the global antibacterial drugs industry in 2014. The global macrolide drugs market is anticipated to expand  at a moderate rate during the forecast period. Key growth drivers for the market include the increasing prevalence of infectious diseases, growing elderly population, increasing number of multidrug-resistant bacterial strains, and higher benefits over traditional antibiotics. Most developed economies such as the U.S., Japan, and countries of Western Europe have large elderly population that is more prone to various bacterial infections primarily caused by low immunity. Also, macrolides exhibit different characteristics such as good oral absorption, easy absorption in tissues, easier dosage of once or twice a day, and lower incidence of side-effects. These make macrolides more useful that other antibacterial drugs. Also, they can be utilized widely to treat mild-to-moderate bacterial infections. However, in some cases, liver injuries have been observed due to usage of macrolides. This factor along with patent expiries and influx of generic drugs may restrain the market for macrolide drugs during the forecast period.

The global macrolide drugs market can be segmented based on type of drug, distribution channel, and region. Based on type of drug, the market has been divided into drugs such as erythromycin, clarithromycin, azithromycin, dirithromycin, roxithromycin, troleandomycin, fidaxomicin, and telithromycin. Based on distribution channel, the market has been classified into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies.

Geographically, the global macrolide drugs market can be segmented into five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Rest of World (RoW).  Asia Pacific held the leading market share, followed by North America, in 2016. These two regions are expected to retain their positions from 2017 to 2025. Rising prevalence of bacterial infection and increasing government initiatives that appear to be moving toward shorter periods of patent exclusivity for new drug applications are some of the factors driving the market in these regions. Moreover, large population, increasing disposable income, and growing patient awareness are some of the other factors driving the market in Asia Pacific. Europe and Rest of the World are likely to present significant growth opportunities in the macrolide drugs market. This is attributable to increasing geriatric population in these regions, which is more prone to bacterial infections triggered by low immunity.

Key players operating in the global macrolide drugs market are Eli Lilly & Co., Pfizer, Inc., Sanofi, Merck & Co., Inc., Abbott Laboratories, and Akorn, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market       

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074